;PMID: 1001810
;source_file_665.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)section:[e:48..169] = [t:48..169]
;2)section:[e:173..192] = [t:173..192]
;3)sentence:[e:196..416] = [t:196..416]
;4)sentence:[e:417..531] = [t:417..531]
;5)sentence:[e:532..733] = [t:532..733]
;6)sentence:[e:735..858] = [t:735..858]
;7)sentence:[e:859..1283] = [t:859..1283]
;8)sentence:[e:1284..1394] = [t:1284..1394]
;9)sentence:[e:1395..1714] = [t:1395..1714]
;10)sentence:[e:1715..1855] = [t:1715..1855]
;11)sentence:[e:1856..2058] = [t:1856..2058]
;12)sentence:[e:2059..2138] = [t:2059..2138]
;13)section:[e:2142..2186] = [t:2142..2186]

;section 0 Span:0..42
;Mol Cell Endocrinol. 1976 Dec;6(2):105-15.
(SEC
  (FRAG (NNP:[0..3] Mol) (NNP:[4..8] Cell) (NNP:[9..19] Endocrinol)
        (.:[19..20] .) (CD:[21..25] 1976) (JJ:[26..30] Dec;) (CD:[30..31] 6)
        (NN:[31..32] -LRB-) (NN:[32..33] 2) (-RRB-:[33..34] -RRB-)
        (::[34..35] :) (CD:[35..37] 10) (CD:[37..41] 5-15) (.:[41..42] .)))

;section 1 Span:48..169
;Cytochrome P-450 and the aromatization of 16alpha-hydroxytestosterone and 
;androstenedione by human placental microsomes.
;[48..64]:cyp450:"Cytochrome P-450"
;[90..117]:substance:"16alpha-hydroxytestosterone"
;[123..138]:substance:"androstenedione"
(SEC
  (NP-HLN
    (NP (NN:[48..58] Cytochrome) (NN:[59..64] P-450))
    (CC:[65..68] and)
    (NP
      (NP (DT:[69..72] the) (NN:[73..86] aromatization))
      (PP (IN:[87..89] of)
        (NP (NN:[90..117] 16alpha-hydroxytestosterone) (CC:[118..121] and)
            (NN:[123..138] androstenedione)))
      (PP (IN:[139..141] by)
        (NP (JJ:[142..147] human) (JJ:[148..157] placental)
            (NNS:[158..168] microsomes))))
    (.:[168..169] .)))
;ERROR_Entity in section[48..64]:cyp450 "Cytochrome P-450"
;ERROR_Entity in section[90..117]:substance "16alpha-hydroxytestosterone"
;ERROR_Entity in section[123..138]:substance "androstenedione"

;section 2 Span:173..192
;Canick JA, Ryan KJ.
(SEC
  (FRAG (NNP:[173..179] Canick) (NNP:[180..182] JA) (,:[182..183] ,)
        (NNP:[184..188] Ryan) (NNP:[189..192] KJ.)))

;sentence 3 Span:196..416
;When measured in vitro using human placental microsomal preparations, the 
;aromatization of 16alpha-hydroxytestosterone to estriol and androstenedione
;to  estrone and estradiol proceeds at almost identical initial rates.
;[288..315]:substance:"16alpha-hydroxytestosterone"
;[319..326]:substance:"estriol"
;[331..346]:substance:"androstenedione"
;[351..358]:substance:"estrone"
;[363..372]:substance:"estradiol"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-2 (WRB:[196..200] When))
      (S
        (NP-SBJ-1 (-NONE-:[200..200] *))
        (VP (VBN:[201..209] measured)
          (NP-1 (-NONE-:[209..209] *))
          (ADVP (FW:[210..212] in) (FW:[213..218] vitro))
          (S-MNR
            (NP-SBJ (-NONE-:[218..218] *))
            (VP (VBG:[219..224] using)
              (NP (JJ:[225..230] human) (JJ:[231..240] placental)
                  (JJ:[241..251] microsomal) (NNS:[252..264] preparations))))
          (ADVP-TMP-2 (-NONE-:[264..264] *T*)))))
    (,:[264..265] ,)
    (NP-SBJ
      (NP (DT:[266..269] the) (NN:[271..284] aromatization))
      (PP (IN:[285..287] of)
        (NP
          (NP
            (NP (NN:[288..315] 16alpha-hydroxytestosterone))
            (PP (TO:[316..318] to)
              (NP (NN:[319..326] estriol))))
          (CC:[327..330] and)
          (NP
            (NP (NN:[331..346] androstenedione))
            (PP (TO:[347..349] to)
              (NP (NN:[351..358] estrone) (CC:[359..362] and)
                  (NN:[363..372] estradiol)))))))
    (VP (VBZ:[373..381] proceeds)
      (PP (IN:[382..384] at)
        (NP
          (ADJP (RB:[385..391] almost) (JJ:[392..401] identical))
          (JJ:[402..409] initial) (NNS:[410..415] rates))))
    (.:[415..416] .)))

;sentence 4 Span:417..531
;Important  differences between 16alpha-hydroxytestosterone and adrostenedione
;aromatization  are evident, however.
;[448..475]:substance:"16alpha-hydroxytestosterone"
;[480..494]:substance:"adrostenedione"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[417..426] Important) (NNS:[428..439] differences))
      (PP (IN:[440..447] between)
        (NP
          (NP (NN:[448..475] 16alpha-hydroxytestosterone)
            (NML-1 (-NONE-:[475..475] *P*)))
          (CC:[476..479] and)
          (NP (NN:[480..494] adrostenedione)
            (NML-1 (NN:[495..508] aromatization))))))
    (VP (VBP:[510..513] are)
      (ADJP-PRD (JJ:[514..521] evident))
      (,:[521..522] ,)
      (ADVP (RB:[523..530] however)))
    (.:[530..531] .)))

;sentence 5 Span:532..733
;While substantial findings have implicated cytochrome  P-450 in placental
;aromatization, the aromatizaiton of androstenedione is  insensitive to CO
;although it is competitively inhibited by metyrapone.
;[575..592]:cyp450:"cytochrome  P-450"
;[642..657]:substance:"androstenedione"
;[677..679]:substance:"CO"
;[722..732]:substance:"metyrapone"
(SENT
  (S
    (SBAR-ADV (IN:[532..537] While)
      (S
        (NP-SBJ (JJ:[538..549] substantial) (NNS:[550..558] findings))
        (VP (VBP:[559..563] have)
          (VP (VBN:[564..574] implicated)
            (NP (NN:[575..585] cytochrome) (NN:[587..592] P-450))
            (PP (IN:[593..595] in)
              (NP (JJ:[596..605] placental) (NN:[606..619] aromatization)))))))
    (,:[619..620] ,)
    (NP-SBJ
      (NP (DT:[621..624] the) (NN:[625..638] aromatizaiton))
      (PP (IN:[639..641] of)
        (NP (NN:[642..657] androstenedione))))
    (VP (VBZ:[658..660] is)
      (ADJP-PRD (JJ:[662..673] insensitive)
        (PP (TO:[674..676] to)
          (NP (NN:[677..679] CO))))
      (SBAR-ADV (IN:[680..688] although)
        (S
          (NP-SBJ-1 (PRP:[689..691] it))
          (VP (VBZ:[692..694] is)
            (ADVP (RB:[695..708] competitively))
            (VP (VBN:[709..718] inhibited)
              (NP-1 (-NONE-:[718..718] *))
              (PP (IN:[719..721] by)
                (NP-LGS (NN:[722..732] metyrapone))))))))
    (.:[732..733] .)))

;sentence 6 Span:735..858
;16alpha-Hydroxytestosterone aromatization, in contrast, is inhibited 50-60%
;by  CO and is strongly inhibited by metyrapone.
;[735..762]:substance:"16alpha-Hydroxytestosterone"
;[804..810]:quantitative-value:"50-60%"
;[815..817]:substance:"CO"
;[847..857]:substance:"metyrapone"
(SENT
  (S
    (NP-SBJ-1 (NN:[735..762] 16alpha-Hydroxytestosterone)
              (NN:[763..776] aromatization))
    (,:[776..777] ,)
    (PP (IN:[778..780] in)
      (NP (NN:[781..789] contrast)))
    (,:[789..790] ,)
    (VP
      (VP (VBZ:[791..793] is)
        (VP (VBN:[794..803] inhibited)
          (NP-1 (-NONE-:[803..803] *))
          (NP-EXT
            (QP (CD:[804..806] 50) (HYPH:[806..807] -) (CD:[807..809] 60))
            (NN:[809..810] %))
          (PP (IN:[811..813] by)
            (NP-LGS (NN:[815..817] CO)))))
      (CC:[818..821] and)
      (VP (VBZ:[822..824] is)
        (ADVP (RB:[825..833] strongly))
        (VP (VBN:[834..843] inhibited)
          (NP-1 (-NONE-:[843..843] *))
          (PP (IN:[844..846] by)
            (NP-LGS (NN:[847..857] metyrapone))))))
    (.:[857..858] .)))

;sentence 7 Span:859..1283
;16alpha-hydroxytestosterone  aromatization is strongly inhibited in a
;competitive manner by androstenedione,  while 16alpha-hydroxytestosterone has
;essentially no effect on androstenedione  aromatization, althogh at very high
;16alpha-hydroxytestosterone concentrations  (65 muM) and subsaturating
;androstenedione concentrations,  16alpha-hydroxytestosterone appears to
;noncomptitively inhibit androstenedione  aromatization.
;[859..886]:substance:"16alpha-hydroxytestosterone"
;[951..966]:substance:"androstenedione"
;[975..1002]:substance:"16alpha-hydroxytestosterone"
;[1032..1047]:substance:"androstenedione"
;[1085..1112]:substance:"16alpha-hydroxytestosterone"
;[1130..1132]:quantitative-value:"65"
;[1133..1136]:quantitative-units:"muM"
;[1156..1171]:substance:"androstenedione"
;[1189..1216]:substance:"16alpha-hydroxytestosterone"
;[1252..1267]:substance:"androstenedione"
(SENT
  (S
    (NP-SBJ-1 (NN:[859..886] 16alpha-hydroxytestosterone)
              (NN:[888..901] aromatization))
    (VP (VBZ:[902..904] is)
      (ADVP (RB:[905..913] strongly))
      (VP (VBN:[914..923] inhibited)
        (NP-1 (-NONE-:[923..923] *))
        (PP (IN:[924..926] in)
          (NP (DT:[927..928] a) (JJ:[929..940] competitive)
              (NN:[941..947] manner)))
        (PP (IN:[948..950] by)
          (NP-LGS (NN:[951..966] androstenedione)))
        (,:[966..967] ,)
        (SBAR-ADV (IN:[969..974] while)
          (S
            (NP-SBJ (NN:[975..1002] 16alpha-hydroxytestosterone))
            (VP (VBZ:[1003..1006] has)
              (NP
                (NP
                  (ADVP (RB:[1007..1018] essentially))
                  (DT:[1019..1021] no) (NN:[1022..1028] effect))
                (PP (IN:[1029..1031] on)
                  (NP (NN:[1032..1047] androstenedione)
                      (NN:[1049..1062] aromatization))))
              (,:[1062..1063] ,)
              (SBAR-ADV (IN:[1064..1071] althogh)
                (S
                  (PP (IN:[1072..1074] at)
                    (NP
                      (NP
                        (ADJP (RB:[1075..1079] very) (JJ:[1080..1084] high))
                        (NN:[1085..1112] 16alpha-hydroxytestosterone)
                         (NNS:[1113..1127] concentrations)
                        (PRN (-LRB-:[1129..1130] -LRB-)
                          (NP (CD:[1130..1132] 65) (NN:[1133..1136] muM))
                          (-RRB-:[1136..1137] -RRB-)))
                      (CC:[1138..1141] and)
                      (NP (JJ:[1142..1155] subsaturating)
                          (NN:[1156..1171] androstenedione)
                          (NNS:[1172..1186] concentrations))))
                  (,:[1186..1187] ,)
                  (NP-SBJ-2 (NN:[1189..1216] 16alpha-hydroxytestosterone))
                  (VP (VBZ:[1217..1224] appears)
                    (S
                      (NP-SBJ-2 (-NONE-:[1224..1224] *))
                      (VP (TO:[1225..1227] to)
                        (ADVP (RB:[1228..1243] noncomptitively))
                        (VP (VB:[1244..1251] inhibit)
                          (NP (NN:[1252..1267] androstenedione)
                              (NN:[1269..1282] aromatization)))))))))))))
    (.:[1282..1283] .)))

;sentence 8 Span:1284..1394
;The apparent Km for the aromatization of androstenedione is 95 nM  and for
;16alpha-hydroxytestosterone, 7 muM.
;[1297..1299]:quantitative-name:"Km"
;[1325..1340]:substance:"androstenedione"
;[1344..1346]:quantitative-value:"95"
;[1347..1349]:quantitative-units:"nM"
;[1359..1386]:substance:"16alpha-hydroxytestosterone"
;[1388..1389]:quantitative-value:"7"
;[1390..1393]:quantitative-units:"muM"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1284..1287] The) (JJ:[1288..1296] apparent)
            (NN:[1297..1299] Km))
        (PP=1 (IN:[1300..1303] for)
          (NP
            (NP (DT:[1304..1307] the) (NN:[1308..1321] aromatization))
            (PP (IN:[1322..1324] of)
              (NP (NN:[1325..1340] androstenedione))))))
      (VP (VBZ:[1341..1343] is)
        (NP-PRD=2 (CD:[1344..1346] 95) (NN:[1347..1349] nM))))
    (CC:[1351..1354] and)
    (S
      (PP=1 (IN:[1355..1358] for)
        (NP (NN:[1359..1386] 16alpha-hydroxytestosterone)))
      (,:[1386..1387] ,)
      (NP-PRD=2 (CD:[1388..1389] 7) (NN:[1390..1393] muM)))
    (.:[1393..1394] .)))

;sentence 9 Span:1395..1714
;Both androstenedione and  16alpha-hydroxytestosterone cause type I spectral
;perturbations associated with  binding to cytochrome P-450 when added to
;placental microsomes; however, the  deltaA390-420 is twice as great in
;response to saturating amounts of  androstenedione than in response to
;16alpha-hydroxytestosterone.
;[1400..1415]:substance:"androstenedione"
;[1421..1448]:substance:"16alpha-hydroxytestosterone"
;[1513..1529]:cyp450:"cytochrome P-450"
;[1650..1665]:substance:"androstenedione"
;[1686..1713]:substance:"16alpha-hydroxytestosterone"
(SENT
  (S
    (S
      (NP-SBJ (CC:[1395..1399] Both) (NN:[1400..1415] androstenedione)
              (CC:[1416..1419] and)
              (NN:[1421..1448] 16alpha-hydroxytestosterone))
      (VP (VBP:[1449..1454] cause)
        (NP
          (NP
            (NML (NN:[1455..1459] type) (CD:[1460..1461] I))
            (JJ:[1462..1470] spectral) (NNS:[1471..1484] perturbations))
          (VP (VBN:[1485..1495] associated)
            (NP (-NONE-:[1495..1495] *))
            (PP-CLR (IN:[1496..1500] with)
              (NP
                (NP (NN:[1502..1509] binding))
                (PP (TO:[1510..1512] to)
                  (NP (NN:[1513..1523] cytochrome) (NN:[1524..1529] P-450)))))))
        (SBAR-ADV
          (WHADVP-2 (WRB:[1530..1534] when))
          (S
            (NP-SBJ-1 (-NONE-:[1534..1534] *))
            (VP (VBN:[1535..1540] added)
              (NP-1 (-NONE-:[1540..1540] *))
              (PP (TO:[1541..1543] to)
                (NP (JJ:[1544..1553] placental) (NNS:[1554..1564] microsomes)))
              (ADVP-TMP-2 (-NONE-:[1564..1564] *T*)))))))
    (::[1564..1565] ;)
    (S
      (ADVP (RB:[1566..1573] however))
      (,:[1573..1574] ,)
      (NP-SBJ (DT:[1575..1578] the) (NN:[1580..1593] deltaA390-420))
      (VP (VBZ:[1594..1596] is)
        (ADJP-PRD
          (ADJP (RB:[1597..1602] twice) (RB:[1603..1605] as)
                (JJ:[1606..1611] great))
          (PP-3 (-NONE-:[1611..1611] *ICH*)))
        (PP (IN:[1612..1614] in)
          (NP
            (NP (NN:[1615..1623] response))
            (PP (TO:[1624..1626] to)
              (NP
                (NP (VBG:[1627..1637] saturating) (NNS:[1638..1645] amounts))
                (PP (IN:[1646..1648] of)
                  (NP (NN:[1650..1665] androstenedione)))))))
        (PP-3 (IN:[1666..1670] than)
          (PP (IN:[1671..1673] in)
            (NP
              (NP (NN:[1674..1682] response))
              (PP (TO:[1683..1685] to)
                (NP (NN:[1686..1713] 16alpha-hydroxytestosterone))))))))
    (.:[1713..1714] .)))

;sentence 10 Span:1715..1855
;If  androstenedione is added to 16alpha-hydroxytestosterone, the same
;spectral  change as that caused by androstenedione alone is expressed.
;[1719..1734]:substance:"androstenedione"
;[1747..1774]:substance:"16alpha-hydroxytestosterone"
;[1820..1835]:substance:"androstenedione"
(SENT
  (S
    (SBAR-ADV (IN:[1715..1717] If)
      (S
        (NP-SBJ-1 (NN:[1719..1734] androstenedione))
        (VP (VBZ:[1735..1737] is)
          (VP (VBN:[1738..1743] added)
            (NP-1 (-NONE-:[1743..1743] *))
            (PP (TO:[1744..1746] to)
              (NP (NN:[1747..1774] 16alpha-hydroxytestosterone)))))))
    (,:[1774..1775] ,)
    (NP-SBJ-2
      (NP (DT:[1776..1779] the) (JJ:[1780..1784] same)
          (JJ:[1785..1793] spectral) (NN:[1795..1801] change))
      (PP (IN:[1802..1804] as)
        (NP
          (NP (DT:[1805..1809] that))
          (VP (VBN:[1810..1816] caused)
            (NP (-NONE-:[1816..1816] *))
            (PP (IN:[1817..1819] by)
              (NP-LGS
                (NP (NN:[1820..1835] androstenedione))
                (ADVP (RB:[1836..1841] alone))))))))
    (VP (VBZ:[1842..1844] is)
      (VP (VBN:[1845..1854] expressed)
        (NP-2 (-NONE-:[1854..1854] *))))
    (.:[1854..1855] .)))

;sentence 11 Span:1856..2058
;The apparent  spectral dissociation constant for androstenedione is 93 nM
;while for  16alpha-hydroxytestosterone it is 11muM; both essentially the same
;as the  comparable apparent Kms for aromatization.
;[1870..1900]:quantitative-name:"spectral dissociation constant"
;[1905..1920]:substance:"androstenedione"
;[1924..1926]:quantitative-value:"93"
;[1927..1929]:quantitative-units:"nM"
;[1941..1968]:substance:"16alpha-hydroxytestosterone"
;[1975..1977]:quantitative-value:"11"
;[1977..1980]:quantitative-units:"muM"
;[2036..2039]:quantitative-name:"Kms"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1856..1859] The) (JJ:[1860..1868] apparent)
        
        (NML (JJ:[1870..1878] spectral) (NN:[1879..1891] dissociation))
        (NN:[1892..1900] constant))
      (PP (IN:[1901..1904] for)
        (NP (NN:[1905..1920] androstenedione))))
    (VP (VBZ:[1921..1923] is)
      (NP-PRD (CD:[1924..1926] 93) (NN:[1927..1929] nM))
      (SBAR-ADV (IN:[1930..1935] while)
        (S
          (PP (IN:[1936..1939] for)
            (NP (NN:[1941..1968] 16alpha-hydroxytestosterone)))
          (NP-SBJ (PRP:[1969..1971] it))
          (VP (VBZ:[1972..1974] is)
            (NP-PRD (CD:[1975..1977] 11) (NN:[1977..1980] muM)))))
      (::[1980..1981] ;)
      (S-ADV
        (NP-SBJ (DT:[1982..1986] both))
        (NP-PRD
          (NP
            (ADVP (RB:[1987..1998] essentially))
            (DT:[1999..2002] the) (JJ:[2003..2007] same))
          (PP (IN:[2008..2010] as)
            (NP
              (NP (DT:[2011..2014] the) (JJ:[2016..2026] comparable)
                  (JJ:[2027..2035] apparent) (NNS:[2036..2039] Kms))
              (PP (IN:[2040..2043] for)
                (NP (NN:[2044..2057] aromatization))))))))
    (.:[2057..2058] .)))

;sentence 12 Span:2059..2138
;The evidence suggests the presence of  two aromatase P-450's in human
;placenta.
;[2102..2119]:cyp450:"aromatase P-450's"
(SENT
  (S
    (NP-SBJ (DT:[2059..2062] The) (NN:[2063..2071] evidence))
    (VP (VBZ:[2072..2080] suggests)
      (NP
        (NP (DT:[2081..2084] the) (NN:[2085..2093] presence))
        (PP (IN:[2094..2096] of)
          (NP (CD:[2098..2101] two)
             (NN:[2102..2111] aromatase) (NNS:[2112..2119] P-450's)))
        (PP-LOC (IN:[2120..2122] in)
          (NP (JJ:[2123..2128] human) (NN:[2129..2137] placenta)))))
    (.:[2137..2138] .)))

;section 13 Span:2142..2186
;PMID: 1001810 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2142..2146] PMID) (::[2146..2147] :) (CD:[2148..2155] 1001810)
        (NN:[2156..2157] -LSB-) (NNP:[2157..2163] PubMed) (::[2164..2165] -)
        (NN:[2166..2173] indexed) (IN:[2174..2177] for)
        (NNP:[2178..2186] MEDLINE-RSB-)))
